111 related articles for article (PubMed ID: 10209206)
41. Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations.
Sackett K; Wexler-Cohen Y; Shai Y
J Biol Chem; 2006 Aug; 281(31):21755-21762. PubMed ID: 16751188
[TBL] [Abstract][Full Text] [Related]
42. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
[TBL] [Abstract][Full Text] [Related]
43. The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20.
Biron Z; Khare S; Quadt SR; Hayek Y; Naider F; Anglister J
Biochemistry; 2005 Oct; 44(41):13602-11. PubMed ID: 16216084
[TBL] [Abstract][Full Text] [Related]
44. A trimeric HIV-1 fusion peptide construct which does not self-associate in aqueous solution and which has 15-fold higher membrane fusion rate.
Yang R; Prorok M; Castellino FJ; Weliky DP
J Am Chem Soc; 2004 Nov; 126(45):14722-3. PubMed ID: 15535688
[TBL] [Abstract][Full Text] [Related]
45. Fusion-competent state induced by a C-terminal HIV-1 fusion peptide in cholesterol-rich membranes.
Apellániz B; Nieva JL
Biochim Biophys Acta; 2015 Apr; 1848(4):1014-22. PubMed ID: 25617671
[TBL] [Abstract][Full Text] [Related]
46. The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils.
Wexler-Cohen Y; Sackett K; Shai Y
Biochemistry; 2005 Apr; 44(15):5853-61. PubMed ID: 15823044
[TBL] [Abstract][Full Text] [Related]
47. Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation.
Kalia V; Sarkar S; Gupta P; Montelaro RC
J Virol; 2003 Mar; 77(6):3634-46. PubMed ID: 12610139
[TBL] [Abstract][Full Text] [Related]
48. Conformational mapping of a viral fusion peptide in structure-promoting solvents using circular dichroism and electrospray mass spectrometry.
Waring AJ; Mobley PW; Gordon LM
Proteins; 1998; Suppl 2():38-49. PubMed ID: 9849909
[TBL] [Abstract][Full Text] [Related]
49. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
50. The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide.
Sáez-Cirión A; Nieva JL; Gallaher WR
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):969-78. PubMed ID: 14678604
[TBL] [Abstract][Full Text] [Related]
51. Membrane-induced conformational change during the activation of HIV-1 gp41.
Kliger Y; Peisajovich SG; Blumenthal R; Shai Y
J Mol Biol; 2000 Aug; 301(4):905-14. PubMed ID: 10966795
[TBL] [Abstract][Full Text] [Related]
52. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
53. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
[TBL] [Abstract][Full Text] [Related]
54. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
Malashkevich VN; Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9134-9. PubMed ID: 9689046
[TBL] [Abstract][Full Text] [Related]
55. The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids.
Curtain C; Separovic F; Nielsen K; Craik D; Zhong Y; Kirkpatrick A
Eur Biophys J; 1999; 28(5):427-36. PubMed ID: 10413864
[TBL] [Abstract][Full Text] [Related]
56. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
57. An efficient production and characterization of HIV-1 gp41 ectodomain with fusion peptide in Escherichia coli system.
Lin CH; Lin CH; Chang CC; Wei TS; Cheng SF; Chen SS; Chang DK
J Biotechnol; 2011 Apr; 153(1-2):48-55. PubMed ID: 21419812
[TBL] [Abstract][Full Text] [Related]
58. Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilayers.
Li Y; Tamm LK
Biophys J; 2007 Aug; 93(3):876-85. PubMed ID: 17513369
[TBL] [Abstract][Full Text] [Related]
59. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
60. HIV fusion peptide penetrates, disorders, and softens T-cell membrane mimics.
Tristram-Nagle S; Chan R; Kooijman E; Uppamoochikkal P; Qiang W; Weliky DP; Nagle JF
J Mol Biol; 2010 Sep; 402(1):139-53. PubMed ID: 20655315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
